title: Gefitinib in non-small cell lung carcinoma: a case report of an unusual side effect and complete response in advanced disease.
abstract: Gefitinib is a tyrosine kinase inhibitor, indicated in advanced non-small cell lung cancer in all lines of treatment for patients harboring EGFR mutations. It has a favorable toxicity profile but may induce unexpected adverse effects, such as an infiammatory reaction in the bladder. We report a rare case of hemorrhagic cystitis, an unusual side effect, in a patient with non-small cell lung cancer treated with gefitinib, which did not compromise the clinical response.
authors.affiliation: Department of Medical Oncology Studies, Second University of Naples, Napels, Italy. marilena_laterza@yahoo.it
authors.forename: Maria Maddalena
authors.initials: MM
authors.lastname: Laterza
authors.forename: Bruno
authors.initials: B
authors.lastname: Chiurazzi
authors.forename: MariaFiorella
authors.initials: M
authors.lastname: Brangi
authors.forename: Ferdinando
authors.initials: F
authors.lastname: Riccardi
authors.forename: Giacomo
authors.initials: G
authors.lastname: Cartenì
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D003556:Cystitis / Q000139:chemically induced*; D066246:ErbB Receptors / Q000187:drug effects* / Q000378:metabolism; D019788:Fluorodeoxyglucose F18; D000077156:Gefitinib; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography / Q000379:methods; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011799:Quinazolines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012074:Remission Induction; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D019788:Fluorodeoxyglucose F18; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases; D000077156:Gefitinib